CryptoSlate July 31, 2026

Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug

Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug

Enlivex pledged commercially reasonable efforts to hold the shareholder vote within 60 days, while the second $400 million remains optional.

The post Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug appeared first on CryptoSlate.

You might also like

Vitalik Buterin says ETH should be valued as a st…
Nov 08, 2026 Read
A single AI forecast inflates US power auctions b…
Nov 08, 2026 Read
Mark Zuckerberg Meta AI Predicts ‘Will Crypto Rec…
Nov 08, 2026 Read
This Bitcoin Developer’s Idea Would Make Quantum …
Nov 08, 2026 Read